title: Virus-mediated swapping of zolpidem-insensitive with zolpidem-sensitive GABA(A) receptors in cortical pyramidal cells.
abstract: Recently developed pharmacogenetic and optogenetic approaches, with their own advantages and disadvantages, have become indispensable tools in modern neuroscience. Here, we employed a previously described knock-in mouse line (GABA(A)Rγ2(77I)lox) in which the γ2 subunit of the GABA(A) receptor (GABA(A)R) was mutated to become zolpidem insensitive (γ2(77I)) and used viral vectors to swap γ2(77I) with wild-type, zolpidem-sensitive γ2 subunits (γ2(77F)). The verification of unaltered density and subcellular distribution of the virally introduced γ2 subunits requires their selective labelling. For this we generated six N- and six C-terminal-tagged γ2 subunits, with which cortical cultures of GABA(A)Rγ2(−/−) mice were transduced using lentiviruses. We found that the N-terminal AU1 tag resulted in excellent immunodetection and unimpaired synaptic localization. Unaltered kinetic properties of the AU1-tagged γ2 ((AU1)γ2(77F)) channels were demonstrated with whole-cell patch-clamp recordings of spontaneous IPSCs from cultured cells. Next, we carried out stereotaxic injections of lenti- and adeno-associated viruses containing Cre-recombinase and the (AU1)γ2(77F) subunit (Cre-2A-(AU1)γ2(77F)) into the neocortex of GABA(A)Rγ2(77I)lox mice. Light microscopic immunofluorescence and electron microscopic freeze-fracture replica immunogold labelling demonstrated the efficient immunodetection of the AU1 tag and the normal enrichment of the (AU1)γ2(77F) subunits in perisomatic GABAergic synapses. In line with this,miniature and action potential-evoked IPSCs whole-cell recorded from transduced cells had unaltered amplitudes, kinetics and restored zolpidem sensitivity. Our results obtained with a wide range of structural and functional verification methods reveal unaltered subcellular distributions and functional properties of γ2(77I) and (AU1)γ2(77F) GABA(A)Rs in cortical pyramidal cells. This transgenic–viral pharmacogenetic approach has the advantage that it does not require any extrinsic protein that might endow some unforeseen alterations of the genetically modified cells. In addition, this virus-based approach opens up the possibility of modifying multiple cell types in distinct brain regions and performing alternative recombination-based intersectional genetic manipulations.
authors.affiliation: Division of Cerebral Structure, National Institute for Physiological Sciences, Okazaki 444-8787, Japan.
authors.forename: Mate
authors.initials: M
authors.lastname: Sumegi
authors.forename: Yugo
authors.initials: Y
authors.lastname: Fukazawa
authors.forename: Ko
authors.initials: K
authors.lastname: Matsui
authors.forename: Andrea
authors.initials: A
authors.lastname: Lorincz
authors.forename: Mark D
authors.initials: MD
authors.lastname: Eyre
authors.forename: Zoltan
authors.initials: Z
authors.lastname: Nusser
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Shigemoto
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D002460:Cell Line; D004622:Embryo, Mammalian; D005260:Female; D058785:GABA-A Receptor Agonists / Q000494:pharmacology; D057809:HEK293 Cells; D006801:Humans; D016086:Lentivirus / Q000235:genetics*; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D011247:Pregnancy; D017966:Pyramidal Cells / Q000502:physiology*; D011725:Pyridines / Q000494:pharmacology; D011963:Receptors, GABA-A / Q000502:physiology*; D045522:Recombinases / Q000502:physiology; D014161:Transduction, Genetic; D000077334:Zolpidem
chemical_list: D058785:GABA-A Receptor Agonists; D011725:Pyridines; D011963:Receptors, GABA-A; D045522:Recombinases; D000077334:Zolpidem